12,372 trials
Exercise Induced Bronchospasm
Primary: Maximum Percentage Fall From Post-dose, Pre-exercise Baseline in Forced Expiratory Volume in 1 Second (FEV₁) Observed up to 60 Minutes Post-exercise Challenge — 5.45…
Recurrent Squamous Cell Lung Carcinoma · Stage IV Squamous Cell Lung Carcinoma AJCC v7
Primary: Response Rate in MEDI4736-treated Participants — 16 percentage of participants
Presbyopia
Primary: Percentage of Participants Gaining 3 Lines or More in Mesopic, High-contrast, Binocular DCNVA, Without Losing More Than 5 Letters of Mesopic, High-Contrast, Binocular…
Carcinoma, Transitional Cell
Primary: Objective Response Rate (ORR) - Central Assessment — 19.5; 21.6; 19.4; 23.8 percentage of participants — p==0.6991
Renal Cell Carcinoma
Primary: Disease-free Survival (DFS) as Assessed by the Investigator — NA; NA Months — p=0.0010
Presbyopia
Primary: Percentage of Participants Gaining 3 Lines or More in Mesopic, High-contrast, Binocular Distance-Corrected Near Visual Acuity (DCNVA) at Day 30, Hour 3 — 8.1; 30.7…
Amyloidosis, Familial · Transthyretin Amyloidosis
Primary: Average of Month 6 and Month 12 Percentage Reduction From Baseline in Serum Transthyretin (TTR) — 91.0 percent reduction
ACL Injury · Postoperative Pain
Primary: Postoperative Visual Analogue Scale Scores — 50.4; 40.0 score on a scale
Anthrax
Primary: Geometric Mean Titer (GMT) of Toxin Neutralizing Antibody (TNA) 50% Neutralization Factor (NF50) at Day 64 — 0.765; 0.741; 0.716; 0.330 Titer (TNA NF50)
Acute Leukemia · Myelodysplasia
Primary: Chronic GVHD-free, Relapse-free Survival (CRFS) Probability — 60.2; 60.3; 52.6; 50.6 percentage of participants — p=0.2368
HIV Infections · HIV-1
Primary: Number of Participants With At-least One Adverse Event as a Measure of Safety Until Etravirine (ETR)-Based Treatment Regimen is Commercially Available — 42 Participants
Hemophilia A · Hemophilia B
Primary: Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period — 18.071; 1.666 episodes per participant per year — p=<0.0001
Walking Impairment · Multiple Sclerosis
Primary: Timed 25 Foot Walk (T25FW, Feet/Second): the Proportion of Subjects With a ≥ 20% Increase in Walking Speed (Measured by T25FW) From Baseline at Week 16 (Responder…
Gastric Cancer
Primary: Overall Survival — 16.0; 15.1 Months — p=0.039
Recurrent Vulvovaginal Candidiasis
Primary: Percentage of Subjects With 1 or More Culture-verified Acute VVC Episodes During the Maintenance Phase of the Study in the Intent-to-treat (ITT) Population. — 3.9; 39.4…